177 related articles for article (PubMed ID: 29214878)
1. Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
Li H; Zhang W; Kuang P; Ye Y; Yang J; Dai Y; Lu X; Zheng Y; Liu T
Leuk Lymphoma; 2018 Aug; 59(8):1890-1898. PubMed ID: 29214878
[TBL] [Abstract][Full Text] [Related]
2. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
3. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
4. Loss-of-function but not dominant-negative intragenic
Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
[TBL] [Abstract][Full Text] [Related]
6. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
7. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
[TBL] [Abstract][Full Text] [Related]
8. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
van der Veer A; Zaliova M; Mottadelli F; De Lorenzo P; Te Kronnie G; Harrison CJ; Cavé H; Trka J; Saha V; Schrappe M; Pieters R; Biondi A; Valsecchi MG; Stanulla M; den Boer ML; Cazzaniga G
Blood; 2014 Mar; 123(11):1691-8. PubMed ID: 24366361
[TBL] [Abstract][Full Text] [Related]
9. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
10. [Significance of IKZF1 gene copy number abnormalities in BCR/ABL-negative B-lineage acute lymphoblastic leukemia in children].
Zou Y; Liu XM; Zhang L; Chen YM; Guo Y; Chen XJ; Yang WY; Wang SC; Ruan M; Liu TF; Zhang JY; Liu F; Qi BQ; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Nov; 17(11):1154-9. PubMed ID: 26575870
[TBL] [Abstract][Full Text] [Related]
11. [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia].
Kuang WY; Zheng MC; Li WL; Yang HX; Zhang BS; Wu P
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):538-542. PubMed ID: 30022754
[TBL] [Abstract][Full Text] [Related]
12. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
[TBL] [Abstract][Full Text] [Related]
14. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.
Cazzaniga G; van Delft FW; Lo Nigro L; Ford AM; Score J; Iacobucci I; Mirabile E; Taj M; Colman SM; Biondi A; Greaves M
Blood; 2011 Nov; 118(20):5559-64. PubMed ID: 21960589
[TBL] [Abstract][Full Text] [Related]
15. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
[TBL] [Abstract][Full Text] [Related]
16. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.
Kim M; Park J; Kim DW; Kim YJ; Jeon YW; Yoon JH; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim HJ; Min CK; Cho SG; Kim Y; Lee JW; Han K; Min WS; Lee S
Bone Marrow Transplant; 2015 Mar; 50(3):354-62. PubMed ID: 25501350
[TBL] [Abstract][Full Text] [Related]
17. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
18. IKZF1
Ito Y; Ozawa H; Eto T; Miyamoto T; Kamimura T; Ogawa R; Uchida N; Wake A; Fujisaki T; Ohno Y; Takase K; Okumura H; Takamatsu Y; Kawano N; Akashi K; Nagafuji K
Eur J Haematol; 2023 Jul; 111(1):103-112. PubMed ID: 36991564
[TBL] [Abstract][Full Text] [Related]
19. IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.
Gupta SK; Bakhshi S; Gupta R; Sharma P; Pushpam D; Sahoo RK; Kamal VK
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e666-e673. PubMed ID: 33906825
[TBL] [Abstract][Full Text] [Related]
20. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Waanders E; van der Velden VH; van der Schoot CE; van Leeuwen FN; van Reijmersdal SV; de Haas V; Veerman AJ; van Kessel AG; Hoogerbrugge PM; Kuiper RP; van Dongen JJ
Leukemia; 2011 Feb; 25(2):254-8. PubMed ID: 21102428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
